Diligence memo · auto-generated · as of July 2, 2026
Caradon Therapeutics, Inc.
Caradon Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Caradon Therapeutics, Inc. operates in Biotechnology, based in ENCINITAS.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Caradon Therapeutics, Inc. has raised $559K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $559K on 2026-01-08.
Most recent recorded round closed around 2026-01-08.
Valuation (modeled)modeled
Provath models Caradon Therapeutics, Inc. at approximately $1.0M (range $298K–$2.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.05× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era. Within the normal band (105% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 6 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).
Modeled value ranks above 3% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.